AMGN
Amgen
Phase 3
Estimated
Ocrelizumab (US)
Relapsing-remitting Multiple Sclerosis (RRMS)
T-minus 102 days
Jan 15, 2027
ClinicalTrials.gov
verified 3mo ago
Countdown card →